Real-world efficacy and safety outcomes for patients with relapsed or refractory (R/R) aggressive B-cell non-Hodgkin's lymphoma (aBNHL) treated with commercial tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry Meeting Abstract
| Authors: | Landsburg, D. J.; Frigault, M. J.; Hu, Z. H.; Jaglowski, S.; Locke, F. L.; Ho, C.; Perales, M. A.; Jacobson, C.; Hill, B. T.; Foley, S. R.; Riedell, P. A.; Tiwari, R.; Masood, A.; Lim, S.; Majdan, M.; Pasquini, M. C.; Turtle, C. J. |
| Abstract Title: | Real-world efficacy and safety outcomes for patients with relapsed or refractory (R/R) aggressive B-cell non-Hodgkin's lymphoma (aBNHL) treated with commercial tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry |
| Meeting Title: | 63rd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 138 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Dec 11-14 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2021-11-23 |
| Language: | English |
| ACCESSION: | WOS:000736398801203 |
| DOI: | 10.1182/blood-2021-146397 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 429 -- Hybrid meeting, also took place online -- Source: Wos |
